While the expression of HER2 may be beneficial for HER2-targeted inhibitors, its re-expression in TNBC transfected cells implicates enhanced tumor growth and invasion, both hallmarks of aggressive tumor phenotypes (Li et al., 2020). The gene discussed is ERBB2; the disease is neoplasm.